TECHNICAL FEASIBILITY:
To reduce the manufacturing costs of our medical system, we re-designed some components. Subsequently, the protocol for the extraction of the SVF was optimised and validated for the new design, and we characterised the composition of the SVF obtained. The characterisation of the SVF cell composition isolating using Mecadistem resulted in the draft of a composition patent. An industrialisation plan has also been drafted which included the identification of potential suppliers. Furthermore, we have written the protocol of two clinical studies that will be carried out during Accelerator Phase project to validate the safety and efficacy of intra-cavernosal injection of SVF using our innovative solution.
COMMERCIAL FEASIBILITY:
The commercial feasibility of the project has also been carefully assessed. The assessment confirmed the freedom to operate of our project, the great prospects of the post-prostatectomy erectile dysfunction market and the scarcity of efficient treatments, what highlights this largely unmet clinical need and the opportunity behind it. Our commercial strategy involves both direct and indirect sales as a way to reach all the geographical target regions, and a gradual penetration first in Europe and Australia, and then in the USA and in Asia.
FINANCIAL FEASIBILITY:
We conducted a financial analysis based on revenue stream, commercialisation plan and prostate cancer epidemiology. In our financial model (5-years business projections), we considered two sales scenarios: one conservative and one optimistic. Even in the conservative scenario, we will generate a big turnover, profit and new job positions.
We also estimated our funding needs at €1.88 million, with €1.31 million, from the Accelerator Pilot SME Instrument funds.
The Feasibility Study confirms the technical feasibility and commercial profitability of our project. Moreover, it shows the novelty of our innovation and the great benefits that would bring to patients and the health sector.
